vs
California BanCorp \ CA（BCAL）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
California BanCorp \ CA的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.3倍（$45.9M vs $35.5M），California BanCorp \ CA净利率更高（35.8% vs -304.2%，领先340.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 0.8%），California BanCorp \ CA自由现金流更多（$56.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 44.7%）
太平洋第一控股是依据美国1956年银行控股公司法案成立的美国银行控股集团，总部位于加利福尼亚州欧文市。集团核心业务围绕旗下太平洋第一银行展开，为个人、企业及专业人士提供各类金融服务，目前在加州、亚利桑那州、内华达州和华盛顿州开设了多家网点。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BCAL vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.9M | $35.5M |
| 净利润 | $16.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 48.8% | -304.8% |
| 净利率 | 35.8% | -304.2% |
| 营收同比 | 0.8% | 681.7% |
| 净利润同比 | -2.1% | 39.6% |
| 每股收益（稀释后） | $0.50 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $45.9M | $35.5M | ||
| Q3 25 | $45.2M | $5.2M | ||
| Q2 25 | $44.3M | $19.2M | ||
| Q1 25 | $44.8M | $14.7M | ||
| Q4 24 | $45.5M | $4.5M | ||
| Q3 24 | $38.1M | $26.1M | ||
| Q2 24 | $22.2M | $14.4M | ||
| Q1 24 | $21.9M | $13.8M |
| Q4 25 | $16.4M | $-108.1M | ||
| Q3 25 | $15.7M | $-162.3M | ||
| Q2 25 | $14.1M | $-171.9M | ||
| Q1 25 | $16.9M | $-202.5M | ||
| Q4 24 | $16.8M | $-178.9M | ||
| Q3 24 | $-16.5M | $-95.8M | ||
| Q2 24 | $190.0K | $-97.5M | ||
| Q1 24 | $4.9M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 48.8% | -304.8% | ||
| Q3 25 | 48.3% | -3327.6% | ||
| Q2 25 | 45.3% | -916.8% | ||
| Q1 25 | 52.8% | -1297.9% | ||
| Q4 24 | 52.2% | -4042.4% | ||
| Q3 24 | -59.1% | -377.1% | ||
| Q2 24 | 1.3% | -697.4% | ||
| Q1 24 | 33.1% | -698.4% |
| Q4 25 | 35.8% | -304.2% | ||
| Q3 25 | 34.7% | -3135.3% | ||
| Q2 25 | 31.8% | -894.2% | ||
| Q1 25 | 37.6% | -1373.3% | ||
| Q4 24 | 37.7% | -3935.5% | ||
| Q3 24 | -43.2% | -367.5% | ||
| Q2 24 | 0.9% | -676.6% | ||
| Q1 24 | 22.5% | -662.4% |
| Q4 25 | $0.50 | $-0.17 | ||
| Q3 25 | $0.48 | $-0.36 | ||
| Q2 25 | $0.43 | $-0.41 | ||
| Q1 25 | $0.52 | $-0.50 | ||
| Q4 24 | $0.54 | $-0.56 | ||
| Q3 24 | $-0.59 | $-0.34 | ||
| Q2 24 | $0.01 | $-0.40 | ||
| Q1 24 | $0.26 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $399.9M | $743.3M |
| 总债务越低越好 | $33.8M | $9.6M |
| 股东权益账面价值 | $576.6M | $1.1B |
| 总资产 | $4.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.06× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $399.9M | $743.3M | ||
| Q3 25 | $559.2M | $659.8M | ||
| Q2 25 | $430.1M | $525.1M | ||
| Q1 25 | $439.2M | $500.5M | ||
| Q4 24 | $388.2M | $594.4M | ||
| Q3 24 | $614.4M | $427.6M | ||
| Q2 24 | $104.7M | $474.3M | ||
| Q1 24 | $86.5M | $296.3M |
| Q4 25 | $33.8M | $9.6M | ||
| Q3 25 | $33.4M | $11.9M | ||
| Q2 25 | $52.9M | $14.2M | ||
| Q1 25 | $70.3M | $16.4M | ||
| Q4 24 | $69.7M | $19.0M | ||
| Q3 24 | $69.1M | $20.5M | ||
| Q2 24 | $42.9M | $22.9M | ||
| Q1 24 | $44.9M | — |
| Q4 25 | $576.6M | $1.1B | ||
| Q3 25 | $564.7M | $1.0B | ||
| Q2 25 | $547.6M | $919.1M | ||
| Q1 25 | $531.4M | $933.9M | ||
| Q4 24 | $511.8M | $1.0B | ||
| Q3 24 | $498.1M | $524.6M | ||
| Q2 24 | $293.2M | $584.4M | ||
| Q1 24 | $292.5M | $401.2M |
| Q4 25 | $4.0B | $1.5B | ||
| Q3 25 | $4.1B | $1.4B | ||
| Q2 25 | $4.0B | $1.3B | ||
| Q1 25 | $4.0B | $1.3B | ||
| Q4 24 | $4.0B | $1.4B | ||
| Q3 24 | $4.4B | $726.5M | ||
| Q2 24 | $2.3B | $775.9M | ||
| Q1 24 | $2.3B | $557.8M |
| Q4 25 | 0.06× | 0.01× | ||
| Q3 25 | 0.06× | 0.01× | ||
| Q2 25 | 0.10× | 0.02× | ||
| Q1 25 | 0.13× | 0.02× | ||
| Q4 24 | 0.14× | 0.02× | ||
| Q3 24 | 0.14× | 0.04× | ||
| Q2 24 | 0.15× | 0.04× | ||
| Q1 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $56.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | 124.1% | -133.1% |
| 资本支出强度资本支出/营收 | 0.8% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.49× | — |
| 过去12个月自由现金流最近4个季度 | $93.1M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $57.3M | $-46.1M | ||
| Q3 25 | $16.0M | $-117.4M | ||
| Q2 25 | $13.4M | $-76.4M | ||
| Q1 25 | $7.0M | $-132.0M | ||
| Q4 24 | $50.3M | $-115.4M | ||
| Q3 24 | $18.3M | $-59.2M | ||
| Q2 24 | $309.0K | $-82.2M | ||
| Q1 24 | $8.1M | $-102.3M |
| Q4 25 | $56.9M | $-47.3M | ||
| Q3 25 | $15.9M | $-117.6M | ||
| Q2 25 | $13.4M | $-79.6M | ||
| Q1 25 | $6.9M | $-133.8M | ||
| Q4 24 | $49.7M | $-116.7M | ||
| Q3 24 | $18.1M | $-63.8M | ||
| Q2 24 | $171.0K | $-83.4M | ||
| Q1 24 | $8.0M | $-109.0M |
| Q4 25 | 124.1% | -133.1% | ||
| Q3 25 | 35.1% | -2272.5% | ||
| Q2 25 | 30.2% | -413.9% | ||
| Q1 25 | 15.3% | -907.4% | ||
| Q4 24 | 109.2% | -2567.7% | ||
| Q3 24 | 47.5% | -244.6% | ||
| Q2 24 | 0.8% | -578.5% | ||
| Q1 24 | 36.4% | -789.9% |
| Q4 25 | 0.8% | 3.5% | ||
| Q3 25 | 0.2% | 4.7% | ||
| Q2 25 | 0.1% | 16.4% | ||
| Q1 25 | 0.2% | 12.4% | ||
| Q4 24 | 1.2% | 28.6% | ||
| Q3 24 | 0.5% | 17.5% | ||
| Q2 24 | 0.6% | 8.2% | ||
| Q1 24 | 0.4% | 48.2% |
| Q4 25 | 3.49× | — | ||
| Q3 25 | 1.02× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 3.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.63× | — | ||
| Q1 24 | 1.63× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
